The global growth hormone deficiency (GHD) market is expected to grow from $1.42bn in 2016 to $2.08bn by 2026 at a compound annual growth rate (CAGR) of 3.9%, according to a report by GlobalData.
Titled ‘OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecasts to 2026’, the report covers the seven major markets of the US, France, Germany, Italy, Spain, the UK and Japan.
The launch of long-acting growth hormones, compliance with growth hormones regimen, and better awareness about the disease have been identified as the key factors driving the growth.
The biggest unmet need in the GHD space is the lack of patient compliance to daily growth hormone dosage. This unmet need has boosted innovation in the market, with several pharmaceutical companies developing easier delivery alternatives for patients, explains Edit Kovalcsik, PhD, Healthcare Analyst for GlobalData.
Pharmaceutical companies are focusing on the development of weekly or biweekly long-acting growth hormone drugs, instead of the existing daily growth hormones. Out of the four late-stage pipeline drugs currently under development, two are long-acting.
Long-acting growth hormones are expected to replace the daily growth hormones, capturing more than half of the patient share by the end of the forecast period. Late-stage pipeline drugs, including Pfizer / OPKO’s Lagova (hGH-CTP), Versartis’ somavaratan, and Novo Nordisk’s somapacitan are anticipated to become the highest revenue earners by 2026.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
With the launch of long-acting growth hormones, the need for new drugs will be low in the GHD space. Focus will eventually shift towards the fulfilment of environmental unmet needs, including early diagnosis, disease awareness, and physician education, the report adds.